Despite their insistence that the bar for opioid painkillers must be raised, two FDA advisory committees voted 14-3 Tuesday to recommend approval of Teva Pharmaceutical Industries Ltd.'s Vantrela ER (hydrocodone) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment when alternative options are inadequate.